Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051688 · ClinicalTrials.gov registry record · Phase 2
Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Chiron Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00051688 is a Phase 2 study that was terminated before completion, run by Chiron Corporation.
The verdict
NCT00051688, a Phase 2 study, was terminated before completion, sponsored by Chiron Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
The primary purpose of this study is to determine the best dose of tezacitabine when combined with oxaliplatin in patients with metastatic colorectal cancer. This study will also evaluate tumor response to the combination of anti-cancer drugs.
Interventions
- DRUG oxaliplatin
- DRUG tezacitabine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-06 |
| Est. Completion | 2004-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00051688
The ClinicalTrials.gov registry entry for NCT00051688 describes a study currently listed as terminated, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Chiron Corporation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which oxaliplatin is the first listed.
NCT00051688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00051688 about?
NCT00051688 is a clinical study titled "Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer". The primary purpose of this study is to determine the best dose of tezacitabine when combined with oxaliplatin in patients with metastatic colorectal cancer. This study will also evaluate tumor response to the combination of anti-cancer drugs.
What is the current status of trial NCT00051688?
This trial is currently terminated. It is a Phase 2 study. The study started on 2003-06. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00051688?
The interventions under investigation include: oxaliplatin (DRUG), tezacitabine (DRUG).
Who is sponsoring clinical trial NCT00051688?
This trial is sponsored by Chiron Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.